Replacement - Director/PDMR Shareholding

RNS Number : 8666S

Cambridge Cognition Holdings PLC

29 September 2014

 



The following amendment has been made to the 'Directors/PDMR Shareholding' announcement released on 29 September 2014 at 10.06 under RNS No 8443S. Nick Kerton's total beneficial interest has been corrected to 127,285 Ordinary Shares representing 0.75% of issued share capital of the Company.

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

Directors/PDMR Shareholding

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests, was notified on 26 September 2014 of the following transactions by Directors.

Nick Kerton, Chief Executive Officer, purchased 55,000 ordinary shares at a price of 65.5 pence each. Following this notification, Mr Kerton now has a total beneficial interest of 127,285 Ordinary Shares representing 0.75% of the issued share capital of the Company.

Nick Walters, Chief Financial Officer, purchased 45,000 ordinary shares at a price of 65.5 pence each. Following this notification, Mr Walters has a total beneficial interest of 92,000 Ordinary Shares representing 0.54% of the issued share capital of the Company.

Cambridge Cognition's capital consists of 16,930,556 Ordinary Shares with voting rights. The Company does not hold any Ordinary Shares in Treasury.

Enquiries:

Cambridge Cognition Holdings plc	www.cambridgecognition.com
Nick Kerton, Chief Executive Officer	Tel: [phone]
Nick Walters, Chief Financial Officer
finnCap Ltd (Nomad and Broker)	Tel: [phone]
Matthew Robinson/Henrik Persson/Simon Hicks	(Corporate Finance)
Elizabeth Johnson	(Corporate Broking)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products.  The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic  scientists  in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function.  In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing.  Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families. 

 

END

 

 

RDSEAFNNADKLEFF